Arcutis Biotherapeutics (ARQT) Insider Welgus Sells $16K of Stock

Howard Welgus, an insider at Arcutis Biotherapeutics, Inc. (NasdaqGS: ARQT), sold 635 shares of the company on June 17, 2026. The shares were sold at an average price of $25.67 each, making the transaction worth approximately $16,300. This sale was planned, as indicated by the transaction code.

Insider Buying and Selling at Arcutis Biotherapeutics, Inc.

Howard Welgus's recent sale isn't his only activity. On June 15, 2026, he sold 4,096 shares at $24.41 each in a planned transaction. On the same day, he also acquired 4,096 shares at $7.93 each, which wasn't planned. Another insider, Sue-Jean Lin, sold 4,946 shares at $24.38 on June 15, 2026, also as a planned transaction.

Other Institutional Activity in Arcutis Biotherapeutics

Several institutional investors have recently adjusted their positions in Arcutis Biotherapeutics. Suvretta Capital Management, LLC increased its holdings by 363,000 shares, bringing its total to 12.3 million shares valued at about $290.4 million. BlackRock, Inc. added 100,832 shares, ending with 9.2 million shares worth approximately $216.8 million. Meanwhile, State Street Corp significantly boosted its stake by 807,896 shares, now holding 6.3 million shares valued at $148.3 million.

Arcutis Biotherapeutics, Inc. Stock Up 1.3%

Shares of Arcutis Biotherapeutics are currently trading around $26.32. The company has a market capitalization of $3.21 billion and a forward P/E ratio of 22.21, indicating expectations of future earnings growth. The stock has shown volatility, with a 52-week range between $13.06 and $31.77. Its 50-day moving average is $22.67, while the 200-day moving average is $23.89. The company maintains a current ratio of 2.68 and a quick ratio of 2.26, with a debt-to-equity ratio of 60.47.

Recent Earnings

Arcutis Biotherapeutics reported $415.6 million in revenue, with a growth rate of 60.1%. Despite this, the company is not yet profitable, showing a net margin of -0.57% and a return on equity of -1.43%. The next earnings report is expected on August 5, 2026.

Analysts Set New Price Targets

Analysts have set optimistic price targets for Arcutis Biotherapeutics. On March 2, 2026, Mizuho maintained its buy rating with a $35 target. Similarly, Guggenheim and TD Cowen also upheld their buy ratings, each with a $35 target. HC Wainwright & Co. set a $34 target, and Needham aimed higher with a $36 target. Overall, the consensus among analysts is a strong buy, with a mean target price of $34.63 based on eight opinions.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing treatments for skin diseases. Its main product, ZORYVE, is a topical cream for plaque psoriasis and atopic dermatitis. The company is also working on treatments for seborrheic dermatitis and scalp psoriasis. Headquartered in Westlake Village, California, Arcutis was founded in 2016 and is led by CEO Todd Franklin Watanabe.

Bottom Line

Howard Welgus's planned sale of Arcutis Biotherapeutics shares is part of regular insider activity. The company's stock remains a focus for institutional investors and analysts, reflecting its potential in the biotechnology sector. As always, remember that insider transactions are one of many factors investors consider, and filings like these are backward-looking.